Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIENT-15 sintilimab plus chemotherapy in first-line advanced esophageal squamous cell carcinoma
2020-000533-40Phase 3Terminated
- Sponsor
- Innovent Biologics
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Sintilimab + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: Overall survival. Started Apr 2020; status: terminated.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2020-000533-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000533-40.